However, METTL3 can act either as an oncogene or a tumor suppressor in TC, depending on the specific cellular context, which suggests that approaches to both induce and suppress METTL3 could represent potential treatment options for patients with TC. This evidence concerns the gene METTL3 and neoplasm.